Maintaining functional and behavioral abilities in Alzheimer disease

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Conventional acetylcholinesterase inhibitors for Alzheimer disease have limitations.
• There is a need for multi-acting therapies to address cognitive and behavioral symptoms.
• Galantamine presents a novel dual-mode-of-action therapeutic approach.

Purpose of the Study:

• To evaluate the efficacy of galantamine in treating Alzheimer disease.
• To assess galantamine's impact on cognitive function, daily activities, and behavioral symptoms.
• To determine the long-term functional and behavioral benefits of galantamine.

Main Methods:

• Three pivotal Phase III studies evaluated galantamine's efficacy over 6 months.
• An open-label 12-month study assessed long-term functional ability.
• A 5-month pivotal study specifically investigated galantamine's effect on behavioral symptoms.

Main Results:

• Galantamine demonstrated functional benefits in pivotal Phase III studies.
• Long-term galantamine treatment stabilized instrumental and basic activities of daily living.
• Galantamine significantly slowed the progression of behavioral symptoms in mild-to-moderate Alzheimer disease patients.
• Behavioral benefits correlated with reduced caregiver distress and time.

Conclusions:

• Galantamine offers a dual mechanism of action for Alzheimer disease management.
• The drug provides significant benefits for both cognitive and behavioral symptoms.
• Galantamine improves functional abilities and enhances the quality of life for patients and caregivers.